Unique ID issued by UMIN | UMIN000031984 |
---|---|
Receipt number | R000036382 |
Scientific Title | Safety and usefulness of preoperative administration of oral nutrient containing arginine, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) in patients with colon cancer surgery |
Date of disclosure of the study information | 2018/03/30 |
Last modified on | 2018/03/29 18:23:52 |
Safety and usefulness of preoperative administration of oral nutrient containing arginine, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) in patients with colon cancer surgery
Safety and usefulness of preoperative administration of oral nutrient containing arginine, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) in patients with colon cancer surgery
Safety and usefulness of preoperative administration of oral nutrient containing arginine, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) in patients with colon cancer surgery
Safety and usefulness of preoperative administration of oral nutrient containing arginine, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) in patients with colon cancer surgery
Japan |
colon cancer
Gastrointestinal surgery |
Malignancy
NO
It is aimed to evaluate the safety and usefulness of ingesting a nutritient rich in arginine, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA).
Safety,Efficacy
Surgical site infection (SSI) such as wound infection and intraperitoneal abscess.
Infectious diseases other than SSI such as respiratory infections and urinary tract infections.
Incidence of suture failure.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Food |
Subjects take a new Investigational new food "Impact" of 125 ml / 1 pack 4 packs a day from 6 days before the scheduled operation date to 2 days before the scheduled operation date.
20 | years-old | <= |
85 | years-old | > |
Male and Female
1. Cases diagnosed as histologically colon cancer.
2. Cases who intestinal resection is scheduled.
3. Cases who can eat by oral ingestion.
4. After receiving sufficient explanation for participation in the research, cases that written consent was obtained.
1. Cases with intestinal obstruction and high intestinal stenosis.
2. Duplicated cancer cases.
3. Cases with heart dysfunction, liver dysfunction, and kidney dysfunction.
4. Cases who are prescribed prednisolone 6 mg / day cases of steroid.
5. Pregnant women, breast-feeding cases, and cases that may be pregnant.
6. Cases who are observed clear infection foci before registration.
7. Cases after total gastrectomy.
8. Cases with Parkinson's disease; Hoehn and Yahr scale 3 or more.
9. Cases who are prescribed immunosuppressive drugs.
10. Cases with milk allergy and/or soybeans allergy.
11. Case having diabetes with HbA1c 7.0 or higher.
12. Cases considered inappropriate by researchers.
30
1st name | |
Middle name | |
Last name | Kazuhiro Sakamoto |
Juntendo university
Department of Coloproctological Surgery
3-1-3 Hongo, Bunkyo-ku, Tokyo
03-3813-3111
kazusaka@juntendo.ac.jp
1st name | |
Middle name | |
Last name | Toshiaki Hagiwara |
Juntendo university
Department of Coloproctological Surgery
3-1-3 Hongo, Bunkyo-ku, Tokyo
03-3813-3111
thagiwa@juntendo.ac.jp
Juntendo university Department of Coloproctological Surgery
none
Other
NO
2018 | Year | 03 | Month | 30 | Day |
Unpublished
Open public recruiting
2017 | Year | 03 | Month | 02 | Day |
2017 | Year | 03 | Month | 02 | Day |
2018 | Year | 03 | Month | 29 | Day |
2018 | Year | 03 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036382